

# TETEC

Tissue Engineering Technologies AG

**Name** > TETEC TISSUE ENGINEERING  
TECHNOLOGIES® AG

**Address/P.O. Box** > Aspenhastrasse 18

**Postal Code/City** > 72770 Reutlingen

**Country** > Germany

**Contact Person** > Dr Christian Ebel

**Telephone** > +49-160-984-959-43

**Fax** > +49-7121-1626-249

**Email** > christian.ebel@tetec-ag.de

**Website** > www.tetec-ag.com

**Social Media** > in

**Number of Employees** > 140+

**Founded (year)** > 2000

**Type of Laboratory** > ISO and GMP certified

**Areas of Activity** > Contract manufacturing for ATMPs (advanced therapy medicinal products), cell-based therapies and drug carriers such as hydrogels and collagen matrices, M-ACI (matrix associated chondrocyte implantation)

## The company

Since the foundation of TETEC in 2000 as a biotech spin-off of the University of Tuebingen and the NMI (The Natural and Medical Science Institute) our mission has been to develop, manufacture, and distribute ATMPs in the field of cell therapies. We combine cell and molecular biology knowledge at the highest level.

Today, we are leaders in the European market for cartilage, cell therapies, and suitable biomaterials.

We are an affiliate of AESCULAP AG and a member of the B. Braun group.

## A leader in the production of autologous cell therapies

At TETEC AG, we apply and believe in the innumerable possibilities of cell-based therapies. With NOVOCART® 3D and NOVOCART® Inject the company has brought two proprietary products to the German market, opening new therapeutic options for patients with cartilage defects in the knee and hip, in order to restore their quality of daily life and ability to participate in sports activities.

Since 2003 we have manufactured over 28,000 individual ATMPs and are about to submit an European market authorisation. Furthermore, we are in preparation to enter the Asian Pacific market.

We have strong assets in ATMP development and large manufacturing capacities, operating under a full GMP manufacturing license and ISO 13485 certification with two separate state-of-the-art, multi-purpose manufacturing facilities and a total of 800m<sup>2</sup> of multi-stage clean rooms (C/D) equipped with Class A isolators. In addition, we have dedicated experienced quality control staff and laboratories, proprietary logistics for clinical trials, and a regulatory affairs department.





## TETEC's services for your cell therapy

Our know-how and expertise in developing and producing cell therapies as well as smart biomaterials set new benchmarks in the biotechnology industry. We are conducting extensive research & development programmes in collaboration with several prestigious national and international partners from hospitals, universities, and industry.

We are pleased to share our experience with biotech companies and invite you to approach us for technology transfers, contract manufacturing, product development, clinical trial coordination, and registration of cell therapeutics – from early clinical development to market access.

## Collaborations

TETEC is looking for collaborations with biotech and pharma companies, offering services for product development, tech transfer, manufacturing, and scale-up of cell-based therapies.

As an experienced partner with more than 20 years of experience in the development and production of ATMPs, TETEC supports biotech & pharma companies that are entering the clinical stage with their developmental cell therapies.

Our specialists provide extensive know-how and expertise in the manufacturing and registration of ATMPs, autologous cell therapies, and blood products as well as biohybrid product solutions. Furthermore, we are looking into cell diagnostic solutions, products in advanced wound care, drug development in the therapeutic area of osteoarthritis and sports, medicine/orthopaedics, immunotherapy, cardiovascular indications, and neurosurgery. Please contact us!

### Executive team:

Dr Detlef Schumann,  
Dr Sebastian Braun-Lüdicke,  
Dr Karl Christoph Gaissmaier.